The Effect of Intravesical Lidocaine Solution Versus Placebo as Anesthesia Prior to Intravesical Injection of Onabotulinum Toxin A. A Randomized, Double-blind, Placebo Controlled Cross-over Study
-
- STATUS
- Recruiting
-
- End date
- May 1, 2024
-
- participants needed
- 50
-
- sponsor
- Herlev and Gentofte Hospital
Summary
The purpose of this study is to investigate the effect of Lidocaine solution versus placebo (isotonic Sodium Chloride NaCl) disposed inside the urinary bladder as intravesical anesthesia prior to onabotulinum toxin A injections in the treatment of urgency urinary incontinence.
Description
The aim of the study is to investigate if bladder installed Lidocaine solution have an effect on reported pain during BTX-A injections compared to placebo.
The study participants will be recruited from the existing patient populations enrolled in the BTX-A program of the tertiary Urogynaecological Clinic of Herlev University Hospital.
The participants are randomized to:
- Active drug: Lidocaine Hydrochloride and Sodium hydrogen carbonate
- Placebo: Sodium Chloride
The study includes 5 study visits:
Visit 1:
- First treatment day
- Randomization
- Registration of pre-treatment pain relief medications: paracetamol, ibuprofen, or other medications. If pre-treatment pain relief is taken before first treatment, same pain relief should be taken before second treatment day (visit 4) in order to reduce bias
- Registration of antibiotic treatment: current antibiotic treatment or long-term prophylactic antibiotic for prevention of recurrent UTI The participant receives the active treatment or placebo, double-blinded
- The participant is asked to grade the intensity of pain according to VAS score immediately after, and when participant has been dressed after the BTX-A injections
Visit 2 (by telephone):
- Phone consultation 1 week after treatment:
- The participant's experience on the procedure on a 5-point ordinal scale: "1- very unsatisfied", "2- unsatisfied", "3- neither unsatisfied or satisfied", "4- satisfied", "5-very satisfied"
Side effects:
- Questions on symptoms of UTI: dysuria, cloudy urine, pollakiuria, nocturia
- Hematuria
- Inability to empty the bladder
- Other symptoms
(Visit 3:)
- The participant contacts the Clinic for next treatment approximately 6-12 months later
- Sponsor or investigator from the Urogynecological Clinic reach out for the participant asking on symptoms of UUI if the participant has not contacted the clinic within 12 months
Visit 4:
- Second treatment day
- The participant receives the opposite treatment, still double-blinded
- Registration of pre-treatment pain relief medications: paracetamol, ibuprofen, or other medications
- Registration of antibiotic treatment: current antibiotic treatment or long-term prophylactic antibiotic for prevention of recurrent UTI
- The participant is asked to grade the intensity of pain according to VAS score immediately after, and when participant has been dressed after the BTX-A injections
Visit 5(by telephone):
- Phone consultation 1 week after treatment:
- The participant's experience on the procedure on a 5-point scale: "1- very unsatisfied", "2- unsatisfied", "3- neither unsatisfied or satisfied", "4- satisfied", "5-very satisfied"
Side effects:
- Questions on symptoms of UTI: dysuria, cloudy urine, pollakiuria nocturia,
- Hematuria
- Inability to empty the bladder
- Other symptoms
Details
| Condition | Urge Incontinence, Overactive Bladder, Anesthesia, Local, Pain, Procedural, Urinary Tract Infections, Hematuria |
|---|---|
| Treatment | Alkalinized Lidocaine, Placebo Sodium Chloride 0.9% Inj |
| Clinical Study Identifier | NCT05415865 |
| Sponsor | Herlev and Gentofte Hospital |
| Last Modified on | 12 October 2022 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer